Stimulation of Sigma-1 receptor by dehydroepiandrosterone ameliorates hypertension-induced kidney hypertrophy in ovariectomized rats

Experimental Biology and Medicine

Volumn 235, Issue 3, 2010, Pages 356-364

  Bhuiyan, Md Shenuarin ^a   Fukunaga, Kohji ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Dehydroepiandrosterone; Endothelial nitric oxide synthase; Kidney hypertrophy; Ovariectomy; Protein kinase B; Sigma 1 receptor

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; PRASTERONE; PROTEIN KINASE B; SERINE; SIGMA 1 OPIATE RECEPTOR; THREONINE;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA STENOSIS; ARTERIAL PRESSURE; ARTICLE; BODY WEIGHT; DISEASE MODEL; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; HEART RATE; HYPERTENSION; KIDNEY HYPERTROPHY; KIDNEY MASS; NONHUMAN; OVARIECTOMY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; RENAL ARTERY;

ANIMALS; AORTA, ABDOMINAL; AORTIC VALVE STENOSIS; BLOOD PRESSURE; BODY WEIGHT; DEHYDROEPIANDROSTERONE; FEMALE; HYPERTENSION; HYPERTROPHY; OVARIECTOMY; PHOSPHORYLATION; RATS; RATS, WISTAR; RECEPTORS, SIGMA; RENAL ARTERY;

RATTUS; RATTUS NORVEGICUS;

EID: 77950190307     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2009.009177     Document Type: Article

References (65)

1. Silbiger S, Neugarten J. The impact of gender on the progression of chronic renal disease. Am J Kidney Dis 1995;25:515-533
2. Silbiger S, Neugarten J. The role of gender in the progression of renal disease. Adv Ren Replace Ther 2003;10:3-14
3. Neugarten J, Silbiger S. The impact of gender on renal transplantation. Transplantation 1994;58:1145-1152
4. Neugarten J, Silbiger S. Effects of sex hormones on mesangial cells. Am J Kidney Dis 1995;26:147-151
5. Seliger SL, Davis C, Stehman-Breen C. Gender and the progression of renal disease. Curr Opin Nephrol Hypertens 2001;10:219-225
6. Neugarten J. Gender and the progression of renal disease. J Am Soc Nephrol 2002;13:2807-2809
7. WassertheiI-Smoller S, Anderson G, Psaty BM, Black HR, Manson J, Wong N, Francis J, Grimm R, Kotchen T, Langer R, Lasser N. Hypertension and its treatment in postmenopausal women: baseline data from the women's health initiative. Hypertension 2000;36:780-789
8. Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 2003;41:1341-1345
9. Schulman IH, Aranda P, Raij L, Veronesi M, Aranda FJ, Martin R. Surgical menopause increases salt sensitivity of blood pressure. Hypertension 2006;47:1168-1174
10. Reckelhoff JF, Zhang H, Srivastava K, Granger JP. Gender differences in hypertension in spontaneously hypertensive rats: role of androgens and androgen receptor. Hypertension 1999;34:920-923
11. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002;288:321-333
12. Pluchino N, Ninni F, Stomati M, Freschi L, Casarosa E, Valentino V, Luisi S, Genazzani AD, Potì E, Genazzani AR. One-year therapy with 10 mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu. Maturitas 2008;59:293-303
13. Genazzani AD, Lanzoni C, Genazzani AR. Might DHEA be a beneficial replacement therapy in the elderly? Drugs Aging 2007;24:173-185
14. Mortola JF, Yen SCC. The effects of oral dehydroepiandrosterone on endocrine-metabolic in postmenopausal women. J Clin Endocrinol Metab 1990;71:696-704
15. Hinson JP, Raven PW. DHEA deficiency syndrome: a new term for old age? J Endocrinol 1999;163:1-5
16. Kibaly C, Meyer L, Patte-Mensah C, Mensah-Nyagan AG. Biochemical and functional evidence for the control of pain mechanisms by dehydroepiandrosterone endogenously synthesized in the spinal cord. FASEB J 2008;22:93-104
17. Tomaszewski M, Charchar FJ, Maric C, Kuzniewicz R, Gola M, Grzeszczak W, Samani NJ, Zukowska-Szczechowska E. Inverse associations between androgens and renal function: the young men cardiovascular association (YMCA) study. Am J Hypertens 2009;22:100-105
18. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005;26:833-876
19. Fukui M, Kitagawa Y, Nakamura N, Kadono M, Yoshida M, Hirata C, Wada K, Hasegawa G, Yoshikawa T. Serum dehydroepiandrosterone sulfate concentration and carotid atherosclerosis in men with type 2 diabetes. Atherosclerosis 2005;181:339-344
20. Straub RH, Konecna L, Hrach S, Rothe G, Kreutz M, Schölmerich J, Falk W, Lang B. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metabol 1998;83:2012-2017
21. Kawano H, Yasue H, Kitagawa A, Hirai N, Yoshida T, Soejima H, Miyamoto S, Nakano M, Ogawa H. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab 2003;88:3190-3195
22. Yamanaka N, Shimizu A. Role of glomerular endothelial damage in progressive renal disease. Kidney Blood Press Res 1999;22:13-20
23. Tchernof A, Labrie F. Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies. Eur J Endocrinol 2004;151:1-14
24. Fukui M, Kitagawa Y, Kamiuchi K, Hasegawa G, Yoshikawa T, Nakamura N. Low serum dehydroepiandrosterone sulfate concentration is a predictor for deterioration of urinary albumin excretion in male patients with type 2 diabetes. Diabetes Res Clin Pract 2006;73:47-50
25. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994;63:451-486
26. Meikle AW, Dorchuck RW, Araneo BA, Stringham JD, Evans TG, Spruance SL, Daynes RA. The presence of a dehydroepiandrosterone-specific receptor binding complex in murine T cells. J Steroid Biochem Mol Biol 1992;42:293-304
27. Okabe T, Haji M, Takayanagi R, Adachi M, Imasaki K, Kurimoto F, Watanabe T, Nawata H. Up-regulation of high-affinity dehydroepiandrosterone binding activity by dehydroepiandrosterone in activated human T lymphocytes. J Clin Endocrinol Metab 1995;80:2993-2996
28. 3H] DHEA binding in rat liver. Biochem Biophys Res Commun 1988;156:22-29
29. Kawai S, Yahata N, Nishida S, Nagai K, Mizushima Y. Dehydroepiandrosterone inhibits B16 mouse melanoma cell growth by induction of differentiation. Anticancer Res 1995;15:427-431
30. Hayashi T, Esaki T, Muto E, Kano H, Asai Y, Thakur NK, Sumi D, Jayachandran M, Iguchi A. Dehydroepiandrosterone retards atherosclerosis formation through its conversion to estrogen: the possible role of nitric oxide. Arterioscler Thromb Vasc Biol 2000;20:782-792
31. Williams MR, Ling S, Dawood T, Hashimura K, Dai A, Li H, Liu JP, Funder JW, Sudhir K, Komesaroff PA. Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs. J Clin Endocrinol Metab 2002;87:176-181
32. Simoncini T, Mannella P, Fornari L, Varone G, Caruso A, Genazzani AR. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology 2003;144:3449-3455
33. Liu D, Dillon JS. Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor. Steroids 2004;69:279-289
34. i2,3. J Biol Chem 2002;277:21379-21388
35. Williams MR, Dawood T, Ling S, Dai A, Lew R, Myles K, Funder JW, Sudhir K, Komesaroff PA. Dehydroepiandrosterone increases endothelial cell proliferation in vitro and improves endothelial function in vivo by mechanisms independent of androgen and estrogen receptors. J Clin Endocrinol Metab 2004;89:4708-4715
36. Zapata E, Ventura JL, De la Cruz K, Rodriguez E, Damian P, Masso F, Montano LF, Lopez-Marure R. Dehydroepiandrosterone inhibits the proliferation of human umbilical vein endothelial cells by enhancing the expression of p53 and p21, restricting the phosphorylation of retinoblastoma protein, and is androgen- and estrogen-receptor independent. FEBS J 2005;272:1343-1353
37. i protein-dependent activation of phosphatidylinositol 3-kinase/Akt and regulation of antiapoptotic Bcl-2 expression. Endocrinology 2007;148:3068-3076
38. Ueda H, Yoshida A, Tokuyama S, Mizuno K, Maruo J, Matsuno K, Mita S. Neurosteroids stimulate G protein-coupled sigma receptors in mouse brain synaptic membrane. Neurosci Res 2001;41:33-40
39. Maurice T, Gregoire C, Espallergues J. Neuro(active)steroids actions at the neuromodulatory sigmal (sigma 1) receptor: biochemical and physiological evidences, consequences in neuroprotection. Pharmacol Biochem Behav 2006;84:581-597
40. Cheng ZX, Lan DM, Wu PY, Zhu YH, Dong Y, Ma L, Zheng P. Neurosteroid dehydroepiandrosterone sulphate inhibits persistent sodium currents in rat medial prefrontal cortex via activation of sigma-1 receptors. Exp Neurol 2008;210:128-136
41. Morin-Surun MP, Colin T, avit-Saubie M, Baulieu EE, Monnet FP. Intracellular sigma 1 receptor modulates phospholipase C and protein kinase C activities in brain stem. Proc Natl Acad Sci USA 1999;96:8196-8199
42. Bhuiyan MS, Shioda N, Fukunaga K. Ovariectomy augments pressure overload-induced hypertrophy associated with changes in Akt and nitric oxide synthase signaling pathways in female rats. Am J Physiol Endocrinol Metab 2007;293:E1606-14
43. Bhuiyan MS, Shioda N, Shibuya M, Iwabuchi Y, Fukunaga K. Activation of endothelial nitric oxide synthase by a vanadium compound ameliorates pressure overload-induced cardiac injury in ovariectomized rats. Hypertension 2009;53:57-63
44. Wang L, Duncan G. Silencing of sigma-1 receptor induces cell death in human lens cells. Exp Cell Res 2006;312:1439-1446
45. Spruce BA, Campbell LA, McTavish N, Cooper MA, Appleyard MV, O'Neill M, Howie J, Samson J, Watt S, Murray K, McLean D, Leslie NR, Safrany ST, Ferguson MJ, Peters JA, Prescott AR, Box G, Hayes A, Nutley B, Raynaud F, Downes CP, Lambert JJ, Thompson AM, Eccles S. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res 2004;64:4875-4886
46. Bhuiyan MS, Shioda N, Fukunaga K. Chronic b-adrenoceptor activation-induced calpain activation and impaired eNOS-Akt signaling mediates cardiac injury in ovariectomized in female rats. Expert Opin Ther Targets 2009;13:275-286
47. Yamada J, Sakuma M, Suga T. Assay of fatty acid ω-hydroxylation using high performance liquid chromatography with fluorescence labeling reagent, 3-bromomethyl-7-methoxy-1,4-benzoxazin-2-one (BrMB). Anal Biochem 1991;199:132-136
48. Dobonneuil EH, Quillard J, Baulieu EE. Hypoxia and dehydroepiandrosterone in old age: a mouse survival study. Respiratory Res 2006;7:144
49. Bonnet S, Dumas-de-La-Roque E, Béguerat H, Marthan R, Fayon M, Santos PD, Savineau JP, Baulieu EE. Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension. Proc Natl Acad Sci USA 2003;100:9488-9493
50. Baulieu EE. Dehydroepiandrosterone (DHEA): a fountain of youth? J Clin Endocrinol Metab 1996;88:3147-3151
51. Longcope C. Metabolism of dehydroepiandrosterone. Ann NY Acad Sci 1995;774:143-148
52. Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M, Sessa WC, Bender JR. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3K-Akt pathway in human endothelial cells. Circ Res 2000;87:677-682
53. Fulton D, Gratton J-P, McCabe TJ, Fontana J, Fujio Y,Walsh K, Franke TF, Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature (Lond) 1999;399:597-601
54. Fulton D, Gratton J-P, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther 2001;299:818-824
55. Ono H, Ono Y, Frohlich ED. Nitric oxide synthase inhibition in spontaneously hypertensive rats. Systemic, renal, and glomerular hemodynamics. Hypertension 1995;26:249-255
56. Hayakawa H, Raij L. Nitric oxide synthase activity and renal injury in genetic hypertension. Hypertension 1998;31:266-270
57. Sindhu RK, Ehdaie A, Vaziri ND, Roberts CK. Effects of chronic renal failure on caveolin-1, guanylate cyclase and Akt protein expression. Biochem Biophys Acta 2004;1690:231-237
58. Buvat J. Androgen therapy with dehydroepiandrosterone. World J Urol 2003;21:346-355
59. Genazzani AD, Stomati M, Bernardi F, Pieri M, Rovati L, Genazzani AR. Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal woman modulates endocrine parameters and synthesis of neuroactive steroids. Fertil Steril 2003;80:1495-1501
60. Swierczynski J, Bannasch P, Mayer D. Increase of lipid peroxidation in rat liver microsomes by dehydroepiandrosterone feeding. Biochim Biophys Acta 1996;1315:193-198
61. Swierczynski J, Mayer D. Dehydroepiandrosterone-induced lipid peroxidation in rat liver mitochondria. J Steroid Biochem Mol Biol 1996;58:599-603
62. Tummala S, Svec F. Correlation between the administered dose of DHEA and serum levels of DHEA and DHEA-S in human volunteers: analysis of published data. Clin Biochem 1999;32:355-361
63. Rao KV, Johnson WD, Bosland MC, Lubet RA, Steele VE, Kelloff GJ, McCormick DL. Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. Cancer Res 1999;59:3084-3089
64. Shilkaitis A, Green A, Punj V, Steele V, Lubet R, Christov K. Dehydroepiandrosterone inhibits the progression phase of mammary carcinogenesis by inducing cellular senescence via a p16-dependent but p53-independent mechanism. Breast Cancer Res 2005;7:R1132-40
65. Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000;101:1539-1545